肾动脉狭窄血运重建的治疗现状及发展趋势

doi:10.12114/j.issn.1007-9572.2022.0507

中国全科医学 ›› 2023, Vol. 26 ›› Issue (11): 1404-1410.DOI: 10.12114/j.issn.1007-9572.2022.0507

肾动脉狭窄血运重建的治疗现状及发展趋势

孟雅琪¹, 刘艳阳¹^,^*(), 田海萍¹, 李婷²

1．010050　内蒙古自治区呼和浩特市，内蒙古医科大学附属医院心血管内科
2．012000　内蒙古乌兰察布中心医院

收稿日期:2022-05-10 修回日期:2022-10-08 出版日期:2023-04-15 发布日期:2022-11-04
通讯作者: 刘艳阳
孟雅琪，刘艳阳，田海萍，等.肾动脉狭窄血运重建的治疗现状及发展趋势[J].中国全科医学，2023，26（11）：1404-1410.[www.chinagp.net]

作者贡献：孟雅琪负责提出文章写作思路，制订检索策略，负责收集与整理文献、撰写论文及论文修订；田海萍、李婷负责文献的收集与整理；刘艳阳负责文章的质量控制及审校，对文章整体负责，监督管理。
基金资助:
内蒙古自治区科技计划项目（202201283）——单中心肾动脉狭窄患者流行病学研究及预后分析

Revascularization in Renal Artery Stenosis: Current Treatments and Outlook

MENG Yaqi¹, LIU Yanyang¹^,^*(), TIAN Haiping¹, LI Ting²

1. Cardiovascular Department, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China
2. Ulanqab Central Hospital, Ulanqab 012000, China

Received:2022-05-10 Revised:2022-10-08 Published:2023-04-15 Online:2022-11-04
Contact: LIU Yanyang
About author:
MENG Y Q, LIU Y Y, TIAN H P, et al. Revascularization in renal artery stenosis: current treatments and outlook [J]. Chinese General Practice, 2023, 26 (11): 1404-1410.

分享到

摘要/Abstract

摘要： 肾动脉狭窄（RAS）为一侧或双侧肾动脉管腔直径减小，可引起肾血管性高血压、缺血性肾病、闪烁性肺水肿等多个系统病变，随诊断水平的提高其越来越受到重视。近年来对于RAS的治疗方法仍不甚明确，血运重建效果有待考量且为相关学科研究热点。本文分析了血运重建在部分研究中效果欠佳的原因和机制，归纳了近年来改善血运重建效果不佳的策略及该领域的新兴辅助治疗方法，强调了患者筛选的重要性，旨在为肾动脉血运重建治疗提供更多的参考资料，为未来临床患者的筛选及治疗有效性的提高提供未来可研究的方向。

关键词: 肾动脉, 肾动脉狭窄, 经皮腔内肾血管成形术, 经皮肾血管重建术, 综述

Abstract:

Renal artery stenosis (RAS) refers to the reduction of lumen diameter of one or both renal arteries, which can cause multiple systemic lesions such as renovascular hypertension, ischemic nephropathy and flash pulmonary oedema. RAS has been attached importance with the improvement of diagnostic level. However, there are still no precise treatments for RAS. As for revascularization, its effect on RAS needs to be evaluated further, and it is also a hot research area. We analyzed the causes and mechanisms regarding the suboptimal effect of renal artery revascularization in some studies, summarized the strategies and neoadjuvant therapies that recently used to improve the effect of renal artery revascularization, with highlights on the importance of selection of patients for the treatment, providing evidence for guiding renal artery revascularization, and for choosing directions in research on patient selection for the treatment and the improvement of treatment effectiveness.

Key words: Renal artery, Renal artery stenosis, Percutaneous renal angioplasty, Renal artery revascularization, Review

孟雅琪,刘艳阳,田海萍,等. 肾动脉狭窄血运重建的治疗现状及发展趋势[J]. 中国全科医学, 2023, 26(11): 1404-1410. DOI: 10.12114/j.issn.1007-9572.2022.0507.
MENG Yaqi,LIU Yanyang,TIAN Haiping, et al. Revascularization in Renal Artery Stenosis: Current Treatments and Outlook[J]. Chinese General Practice, 2023, 26(11): 1404-1410. DOI: 10.12114/j.issn.1007-9572.2022.0507.

参考文献 56

[1]	蒋雄京，邹玉宝. 肾动脉狭窄的诊断和处理中国专家共识[J].中国循环杂志，2017，32(9):835-844.
[2]	ZELLER T, KRANKENBERG H, ERGLIS A，et al. A randomized，multi-center，prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with hemodynamically relevant atherosclerotic renal artery stenosis（RADAR）——one-year results of a pre-maturely terminated study[J]. Trials，2017，18(1):380.
[3]	ASTRAL Investigators, WHEATLEY K, IVES N，et al. Revascularization versus medical therapy for renal-artery Stenosis[J]. N Engl J Med，2009，361(20):1953-1962.
[4]	BAX L, WOITTIEZ AJ J, KOUWENBERG H J，et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial[J]. Ann Intern Med，2009，150(12):840-848.
[5]	COOPER C J, MURPHY T P, CUTLIP D E，et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis[J]. N Engl J Med，2014，370(1):13-22. DOI：10.1056/NEJMoa1310753.
[6]	CAMM A J，LUSCHER T F，MAURER G，et al. The ESC Textbook of Cardiovascular Medicine（3 edn）[EB/OL].（2018-07-01）[2022-10-28].
[7]	PRAJAPATI J S, JAIN S R, JOSHI H，et al. Response of blood pressure after percutaneous transluminal renal artery angioplasty and stenting[J]. World J Cardiol，2013，5(7):247-253.
[8]	CHEN Y H, PAN H R, LUO G Z，et al. Use of percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis：a systematic review and meta-analysis[J]. J Int Med Res，2021，49(1):300060520983585. DOI：10.1177/0300060520983585.
[9]	COURAND P Y, DINIC M, LORTHIOIR A，et al. Resistant hypertension and atherosclerotic renal artery stenosis：effects of angioplasty on ambulatory blood pressure. A retrospective uncontrolled single-center study[J]. Hypertension，2019，74(6):1516-1523. DOI：10.1161/HYPERTENSIONAHA.119.13393.
[10]	TEXTOR S C, MISRA S, ODERICH G S. Percutaneous revascularization for ischemic nephropathy：the past，present，and future[J]. Kidney Int，2013，83(1):28-40.
[11]	FARAHANI R A, AFARIDEH M, ZHU X Y，et al. Percutaneous transluminal renal angioplasty attenuates poststenotic kidney mitochondrial damage in pigs with renal artery stenosis and metabolic syndrome[J]. J Cell Physiol，2021，236(5):4036-4049. DOI：10.1002/jcp.30146.
[12]	NARGESI A A, ZHANG L H, TANG H，et al. Coexisting renal artery stenosis and metabolic syndrome magnifies mitochondrial damage，aggravating poststenotic kidney injury in pigs[J]. J Hypertens，2019，37(10):2061-2073.
[13]	FARAHANI R A, YU S S, FERGUSON C M，et al. Renal revascularization attenuates myocardial mitochondrial damage and improves diastolic function in pigs with metabolic syndrome and renovascular hypertension[J]. J Cardiovasc Transl Res，2022，15(1):15-26. DOI：10.1007/s12265-021-10155-3.
[14]	ABUMOAWAD A, SAAD A, FERGUSON C M，et al. Tissue hypoxia，inflammation，and loss of glomerular filtration rate in human atherosclerotic renovascular disease[J]. Kidney Int，2019，95(4):948-957. DOI：10.1016/j.kint.2018.11.039.
[15]	EIRIN A, GLOVICZKI M L, TANG H，et al. Inflammatory and injury signals released from the post-stenotic human kidney[J].Eur Heart J，2013，34(7):540-548a.
[16]	WANG W, SAAD A, HERRMANN S M，et al. Changes in inflammatory biomarkers after renal revascularization in atherosclerotic renal artery stenosis[J]. Nephrol Dial Transplant，2016，31(9):1437-1443. DOI：10.1093/ndt/gfv448.
[17]	SAAD A, HERRMANN S M S, CRANE J，et al. Stent revascularization restores cortical blood flow and reverses tissue hypoxia in atherosclerotic renal artery stenosis but fails to reverse inflammatory pathways or glomerular filtration rate[J]. Circ Cardiovasc Interv，2013，6(4):428-435. DOI：10.1161/CIRCINTERVENTIONS.113.000219.
[18]	郑斌，吴铮，李文铮. 合并肾动脉狭窄的高血压病患者血炎性因子水平的变化及意义[J]. 中国介入心脏病学杂志，2019，27(3):167-173. DOI：10.3969/j.issn.1004-8812.2019.03.008.
[19]	SAFAR M E. Arterial stiffness as a risk factor for clinical hypertension[J]. Nat Rev Cardiol，2018，15(2):97-105.
[20]	SUN D, EIRIN A, EBRAHIMI B，et al. Early atherosclerosis aggravates renal microvascular loss and fibrosis in swine renal artery stenosis[J]. J Am Soc Hypertens，2016，10(4):325-335.
[21]	NARGESI A A, ZHU X Y, CONLEY S M，et al. Renovascular disease induces mitochondrial damage in swine scattered tubular cells[J]. Am J Physiol Renal Physiol，2019，317(5):F1142-1153. DOI：10.1152/ajprenal.00276.2019.
[22]	NARGESI A A, ZHU X Y, SAADIQ I M，et al. Experimental renovascular disease induces endothelial cell mitochondrial damage and impairs endothelium-dependent relaxation of renal artery segments[J]. Am J Hypertens，2020，33(8):765-774.
[23]	EIRIN A, EBRAHIMI B, ZHANG X，et al. Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease[J]. Cardiovasc Res，2014，103(4):461-472. DOI：10.1093/cvr/cvu157.
[24]	EIRIN A, SAAD A, TANG H，et al. Urinary mitochondrial DNA copy number identifies chronic renal injury in hypertensive patients[J]. Hypertension，2016，68(2):401-410. DOI：10.1161/HYPERTENSIONAHA.116.07849.
[25]	JOURDE-CHICHE N, FAKHOURI F, DOU L，et al. Endothelium structure and function in kidney health and disease[J]. Nat Rev Nephrol，2019，15(2):87-108. DOI：10.1038/s41581-018-0098-z.
[26]	张城林，何蕾，王力，等. 内皮功能障碍的发生机制[J]. 中国科学：生命科学，2022，52(5):691-698. DOI：1.1360/SSV-2021-0251.
[27]	ZACHRISSON K, KRUPIC F, SVENSSON M，et al. Results of renal artery revascularization in the post-ASTRAL era with 4 years mean follow-up[J]. Blood Press，2020，29(5):285-290.
[28]	MOUTINHO M, PEDRO L M, FERNANDES R F E，et al. Is stenting for atherosclerotic renal stenosis an effective technique?[J]. Rev Port Cardiol（Engl Ed），2019，38(12):859-867. DOI：10.1016/j.repc.2019.06.006.
[29]	VASSALLO D, RITCHIE J, GREEN D，et al. The effect of revascularization in patients with anatomically significant atherosclerotic renovascular disease presenting with high-risk clinical features[J]. Nephrol Dial Transplant，2017，33(3):497-506. DOI：10.1093/ndt/gfx025.
[30]	MURPHY T P, COOPER C J, PENCINA K M，et al. Relationship of albuminuria and renal artery stent outcomes: results from the CORAL randomized clinical trial（cardiovascular outcomes with renal artery lesions）[J]. Hypertension，2016，68(5):1145-1152. DOI：10.1161/HYPERTENSIONAHA.116.07744.
[31]	KALRA P A, CHRYSOCHOU C, GREEN D，et al. The benefit of renal artery stenting in patients with atheromatous renovascular disease and advanced chronic kidney disease[J]. Catheter Cardiovasc Interv，2010，75(1):1-10. DOI：10.1002/ccd.22290.
[32]	ABBOUD J, RÖMER A, KASPER W，et al. Percutaneous transluminal renal angioplasty of global kidney ischemia improves renal function and blood pressure[J]. Int J Cardiol Heart Vasc，2020，27:100475. DOI：10.1016/j.ijcha.2020.100475.
[33]	REINHARD M, SCHOUSBOE K, ANDERSEN U B，et al. Renal artery stenting in consecutive high-risk patients with atherosclerotic renovascular disease：a prospective 2-center cohort study[J]. J Am Heart Assoc，2022，11(7):e024421. DOI：10.1161/JAHA.121.024421.
[34]	SAEED A, FORTUNA E N, JENSEN G. Split renal function in patients with unilateral atherosclerotic renal artery stenosis-effect of renal angioplasty[J]. Clin Kidney J，2017，10(4):496-502. DOI：10.1093/ckj/sfx052.
[35]	CHEN Y, DONG H, JIANG X，et al. Percutaneous transluminal angioplasty with selective stenting for the treatment of renal artery stenosis caused by fibromuscular dysplasia:18 years' experience from the China Center for Cardiovascular Disease[J]. Catheter Cardiovasc Interv，2020，95 Suppl 1:641-647. DOI：10.1002/ccd.28679.
[36]	LLOPIS C G, SERRAL A V, CATAL N S B. Síndrome de Pickering:insuficiencia cardiaca aguda con un actor inesperado[J]. Hipertens Y Riesgo Vasc，2021，38(4):197-200.
[37]	KIM Y, LEE S H. Pickering syndrome: renal artery stenosis and recurrent flash pulmonary oedema[J]. QJM，2020，113(6):423-424. DOI：10.1093/qjmed/hcaa013.
[38]	CAREY R M, CALHOUN D A, BAKRIS G L，et al. Resistant hypertension:detection，evaluation，and management:a scientific statement from the American heart association[J]. Hypertension，2018，72(5):e53-90. DOI：10.1161/HYP.0000000000000084.
[39]	TAKAHASHI W, MORITA T, TANAKA K，et al. Determinant role of renal artery stenting in recovery from acute worsening of atherosclerotic renal failure[J]. J Cardiol Cases，2020，24(2):49-51. DOI：10.1016/j.jccase.2020.12.011.
[40]	JOHANSEN K L, GARIMELLA P S, HICKS C W，et al. Central and peripheral arterial diseases in chronic kidney disease:conclusions from a Kidney Disease:improving Global Outcomes（KDIGO）Controversies Conference[J]. Kidney Int，2021，100(1):35-48. DOI：10.1016/j.kint.2021.04.029.
[41]	STRATIGIS S, STYLIANOU K, KYRIAZIS P P，et al. Renal artery stenting for atherosclerotic renal artery stenosis identified in patients with coronary artery disease:does captopril renal scintigraphy predict outcomes?[J]. J Clin Hypertens （Greenwich），2018，20(2):373-381. DOI：10.1111/jch.13160.
[42]	NAKAJIMA Y, KAWARADA O, HIGASHIMORI A，et al. Predictors of cardiac benefits of renal artery stenting from a multicentre retrospective registry[J]. Heart Asia，2017，9(2):e010934. DOI：10.1136/heartasia-2017-010934.
[43]	CHRYSOCHOU C, GREEN D, RITCHIE J，et al. Kidney volume to GFR ratio predicts functional improvement after revascularization in atheromatous renal artery stenosis[J]. PLoS One，2017，12(6):e0177178. DOI：10.1371/journal.pone.0177178.
[44]	LIN Z Y, ZHANG B H, LIN L T，et al. Prediction of split renal function improvement after renal artery stenting by blood oxygen level-dependent magnetic resonance imaging[J]. Front Cardiovasc Med，2022，9:793777. DOI：10.3389/fcvm.2022.793777.
[45]	ZHAO L, LI G Q, MENG F Y，et al. Cortical and medullary oxygenation evaluation of kidneys with renal artery stenosis by BOLD-MRI[J]. PLoS One，2022，17(3):e0264630. DOI：10.1371/journal.pone.0264630.
[46]	IWASHIMA Y, KUSUNOKI H, TANIYAMA A，et al. Impact of percutaneous transluminal renal angioplasty on autonomic nervous system and natriuresis in hypertensive patients with renal artery stenosis[J]. J Am Heart Assoc，2022，11(6):e023655. DOI：10.1161/JAHA.121.023655.
[47]	ZHANG X, KRIER J D, AMADOR CARRASCAL C，et al. Low-energy shockwave therapy improves ischemic kidney microcirculation[J]. J Am Soc Nephrol，2016，27(12):3715-3724. DOI：10.1681/ASN.2015060704.
[48]	CHEN X J, ZHANG X, JIANG K，et al. Improved renal outcomes after revascularization of the stenotic renal artery in pigs by prior treatment with low-energy extracorporeal shockwave therapy[J]. J Hypertens，2019，37(10):2074-2082. DOI：10.1097/HJH.0000000000002158.
[49]	PERICO N, CASIRAGHI F, REMUZZI G. Clinical translation of mesenchymal stromal cell therapies in nephrology[J]. J Am Soc Nephrol，2018，29(2):362-375. DOI：10.1681/ASN.2017070781.
[50]	SAAD A, DIETZ A B, HERRMANN S M S，et al. Autologous mesenchymal stem cells increase cortical perfusion in renovascular disease[J]. J Am Soc Nephrol，2017，28(9):2777-2785. DOI：10.1681/ASN.2017020151.
[51]	ABUMOAWAD A, SAAD A, FERGUSON CM，et al. In a Phase 1a escalating clinical trial，autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure[J]. Kidney Int，2020，97(4):793-804. DOI：10.1016/j.kint.2019.11.022.
[52]	CHEN X J, ZHANG X, JIANG K，et al. Adjunctive mesenchymal stem/stromal cells augment microvascular function in poststenotic kidneys treated with low-energy shockwave therapy[J]. J Cell Physiol，2020，235(12):9806-9818. DOI：10.1002/jcp.29794.
[53]	EIRIN A, LI Z, ZHANG X，et al. A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis[J]. Hypertension，2012，60(5):1242-1249.
[54]	EIRIN A, HERRMANN S M, SAAD A，et al. Urinary mitochondrial DNA copy number identifies renal mitochondrial injury in renovascular hypertensive patients undergoing renal revascularization:a pilot study[J]. Acta Physiol（Oxf），2019，226(3):e13267. DOI：10.1111/apha.13267.
[55]	GUISE E, ENGEL J E, WILLIAMS M L，et al. Biopolymer-delivered vascular endothelial growth factor improves renal outcomes following revascularization[J]. Am J Physiol Renal Physiol，2019，316(5):F1016-1025.
[56]	ENGEL J E, WILLIAMS M L, WILLIAMS E，et al. Recovery of renal function following kidney-specific VEGF therapy in experimental renovascular disease[J]. Am J Nephrol，2020，51(11):891-902. DOI：10.1159/000511260.

肾动脉狭窄血运重建的治疗现状及发展趋势

Revascularization in Renal Artery Stenosis: Current Treatments and Outlook

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 56

相关文章 15

编辑推荐

Metrics

留言

[1]	南子晴, 蔺莉. 妊娠期尿潴留的诊治进展[J]. 中国全科医学, 2023, 26(36): 4608-4612.
[2]	刘颖宏, 杨晓娟. Takayasu动脉炎妊娠期间临床管理的研究进展[J]. 中国全科医学, 2023, 26(35): 4483-4486.
[3]	王小雪, 毛乐乐, 王子君, 杨慕坤, 白文佩, 刁翯. 自体富血小板浓缩物在妇科领域中的应用研究进展[J]. 中国全科医学, 2023, 26(35): 4472-4476.
[4]	刘欣怡, 刘占东. 慢性疲劳综合征相关焦虑及抑郁的研究进展[J]. 中国全科医学, 2023, 26(35): 4477-4482.
[5]	王旭, 魏戌, 朱立国, 冯天笑, 王志鹏, 师彬. 医工结合的中医手法治疗脊柱退行性疾病疗效机制研究：思路与前景[J]. 中国全科医学, 2023, 26(33): 4118-4124.
[6]	辛功恺, 丛欣, 袁磊, 程悦彤, 倪翠萍, 张巍巍, 張平平, 刘宇. 失智症老年人综合评估工具的研究进展[J]. 中国全科医学, 2023, 26(33): 4103-4109.
[7]	张思宇, 周郁秋, 杜晓慧, 王正君. 精神病未治期及其早期干预的研究进展[J]. 中国全科医学, 2023, 26(33): 4110-4117.
[8]	孟江涛, 杨思宇, 孙蕾, 雷瑞宁, 赵晓霞. 弥散张量成像联合运动诱发电位评估脑梗死偏瘫患者运动功能预后价值的研究进展[J]. 中国全科医学, 2023, 26(32): 4098-4102.
[9]	王佳欣, 赵亚利. 国内外医疗团队合作评估工具系统综述[J]. 中国全科医学, 2023, 26(31): 3951-3962.
[10]	卫梦雨, 王佳佳, 张莹莹, 李春阳, 李建生. 阻塞性睡眠呼吸暂停患者报告结局测评工具研究现状分析[J]. 中国全科医学, 2023, 26(30): 3725-3733.
[11]	苑喜微, 南月敏. 线粒体融合蛋白2的结构和功能及其在肝脏疾病中作用机制的研究进展[J]. 中国全科医学, 2023, 26(30): 3841-3846.
[12]	肖雨倩, 白艳杰, 王岩, 陈淑颖, 陈丽敏, 孙可心, 万俊. 线粒体转移在脑卒中后认知障碍中的研究进展[J]. 中国全科医学, 2023, 26(30): 3833-3840.
[13]	刘煜, 岳婷, 杨东宇, 赵中亭, 杨吉勃, 朱田田. 自噬在类风湿关节炎发病机制中的研究进展[J]. 中国全科医学, 2023, 26(29): 3710-3714.
[14]	蒲瑜, 张吉翔, 董卫国. 铁死亡与炎症性肠病的研究进展[J]. 中国全科医学, 2023, 26(29): 3698-3703.
[15]	任延峰, 刘世蒙, 陶颖, 陈英耀. 抑郁症患者药物治疗偏好的系统综述：基于离散选择实验和优劣尺度法[J]. 中国全科医学, 2023, 26(28): 3559-3564.